Compare Gilead Sciences, Inc. (GILD) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Intel Corp — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Intel Corp trades at $99.05 (market cap $492.85B). The key difference: Intel Corp is far larger — about 2.9× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | INTC | |
|---|---|---|
Market Cap | $168.35B | $492.85B |
Sector | Health | Technology |
52-Week High | $155.80 | $140.94 |
52-Week Low | $110.56 | $21.81 |
Enterprise Value | $191.42B | $513.66B |
Dividend Yield | 2.42% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intel (INTC) trades at $97.52, down 4.06% today amid a $20 billion stock offering announcement. Despite recent earnings beats, the stock faces pressure from dilution concerns while showing strong revenue growth in data center and AI segments. Technical indicators are bullish on moving averages but neutral on oscillators, with key resistance at $100. Fundamentals reveal a mixed picture with negative net income margins but improving operational cash flow trends.
The outlook remains cautiously optimistic with a $116.67 analyst price target suggesting 20% upside, though execution risks in foundry losses and competitive pressures persist. Investors should weigh the growth potential in AI against near-term dilution and margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
